http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102370983-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd4f8c06b3d945643fadff8f52b2c3ce |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ef1aa7529ac4d1db45e8c1c89c467ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14ea8bfa39fa479bba165bcd05ba9dc1 |
| publicationDate | 2014-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102370983-B |
| titleOfInvention | Anti-tumor medicine composition and purpose thereof |
| abstract | The invention discloses a solid tumor resisting medicine composition with arctigenin and nitrosourea alkylating agent anti-tumor medicines as active components. The weight ratio of arctigenin to nitrosourea alkylating agent anti-tumor medicines is 1:0.001-1000, and preferably 1:0.01-600. The anti-tumor medicine composition provided by the invention is advantaged in clear components, wide anti-tumor spectrum, substantial treatment effect against various tumors, low price, low side-effects, and good clinical application prospect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3632411-A1 |
| priorityDate | 2010-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 78.